TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Initiation of anxiolytics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Initiation of sedative/hypnotics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: onset time of analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration difficulties
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: 24-h urinary cortisol excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Seizure-freedom
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Decrease in D/24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Postprandial serum insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of eyes with IOP <= 18 mm Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Visual-field damage progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: synovitis scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: new erosions on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Event-Free Survival (EFS) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease-Free Survival (DFS) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Good response to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Better response to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MCV wastage rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ropivacaine plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean diurnal IOP change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of silorane-based composite vs dimethacrylate-based composite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: internal or external rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of minor side-effects
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of first events
Endpoint domain: Adverse events/effects
Primary endpoint: Perceived treatment credibility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Activation of immune function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: skin blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of switch into hypomania or mania
Endpoint domain: Adverse events/effects
Primary endpoint: Diabetes knowledge score change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diabetes awareness score change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-management score change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: risk of at least 1 grade ≥3 adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Duration for Plastibell fall-off
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall sun protection behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sunburns in the past three months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of skin exams by health care provider
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: HU, SUV(mean), and SUV(max) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spine bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative healing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speech understanding performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for ESPrit 3G
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improved ease of use and wearer comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: wheal area reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: flare area reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: itch score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved trunk kinematics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health promotion behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FENO concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of clinical complete remission after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate before surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intrinsic PEEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 30-day mortality following open elective aneurysm repair
Endpoint domain: Mortality/survival
Primary endpoint: Fear of movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neural plasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: iAUC for EPA and DHA in plasma phospholipid fatty acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall treatment time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of eyes with astigmatism of 0.50 D or less
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean postoperative refractive astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Recovery from Discharge (RfD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vascular responses to methacholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Corneal desquamation
Endpoint domain: Adverse events/effects
Primary endpoint: Aggression incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mutuality
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Avoidant reaction to angry faces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: opiate withdrawal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAS28 remission criterion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total joint count (TJC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: self-reported unexplained physical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of violence
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Hamilton Depression Rating Scale (Ham-D) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in HAQ-DI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain control at 2 h postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of nausea within 12‐24 h after surgery
Endpoint domain: Adverse events/effects
Primary endpoint: regression of coronary atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long term progression of Parkinson disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of physical distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ACR20/50 response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDA (Low Disease Activity) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Groin and back pain levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comfort during bedrest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with closure procedure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean FEV1 30-60 minutes post-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Severity of symptoms on Lund-MacKay Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal cavities with nasal secretions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resting muscle Cr and PCr concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: FEV1 (percent predicted)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Decrease in DIS and UDI-6 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of urgency symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AGE-related total fluorescence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein-linked pentosidine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postoperative nausea and vomiting (PONV) in the first hour
Endpoint domain: Adverse events/effects
Primary endpoint: Use of ondansetron for PONV treatment in 24 hours
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: risk of loss of reduction of ≥10 degrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: criteria for remanipulation
Endpoint domain: Adverse events/effects
Primary endpoint: time spent in hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Disease-specific QoL score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Arterial plasma glutamine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Phytohemagglutinin-stimulated lymphocyte proliferative response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in mean arterial pressure by sodium restriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: DAS28(4)-ESR response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percent change of noninflammatory acne lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: average number of rescue doses per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of BTP episodes per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain intensity ratings (current, average, minimum, maximum)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Actuarial survival
Endpoint domain: Mortality/survival
Primary endpoint: Freedom from endocarditis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Freedom from thromboembolic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: reducing symptoms of social and physical impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reducing disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased right amygdala activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PAI‐1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Success rate of percutaneous needle aspiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Curative rate of PCD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-stress stunning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stress induced ischaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of IFN‐alpha antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Beta‐2‐microglobulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower limb injury incidence
Endpoint domain: Adverse events/effects
Primary endpoint: cannabis withdrawal reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Everyday functionality improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: undetectable serum HBV DNA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight gain induced by antipsychotic treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relief of urogenital symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean Tmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intubation duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for supporting manoeuvres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Frequency of Early Childhood Caries (ECC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma fasting glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: motion stimulus required to produce moderate nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: injection pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: horizontal eye motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vertical eye motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospitalizations
Endpoint domain: Adverse events/effects
Primary endpoint: Peak internal rotation moments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak varus moments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Internal rotation impulse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-36 overall score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: self-assessed decrease of back symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: grade 3 or 4 hepatotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Best overall quality in 3D representation of the liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Second molar cervico-occlusal crown height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alveolar ridge thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enrollment in H2H initiative
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: anatomical success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall improvement in QoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Complete sensory block to pinprick
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean LA perineural volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean distance of longitudinal perineural LA spread
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood transfusion capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Inotropic scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum levels of 8‐OHdG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of NOx
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life of isoniazid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AcINH/INH ratio at 3 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak concentration of DDP species
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean residence time (MRT) of DDP species
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of pleural effusion
Endpoint domain: Adverse events/effects
Primary endpoint: FD (Fistula Development)
Endpoint domain: Adverse events/effects
Primary endpoint: Seroma
Endpoint domain: Adverse events/effects
Primary endpoint: Nonhealing incisional wound
Endpoint domain: Adverse events/effects
Primary endpoint: Degree of scar pruritus evaluated by the Visual Analogue Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores of scar pruritus location, extent, frequency, and sleep effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment satisfaction of scar pruritus
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum levels of CXCL10 (IP-10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Airway sealing pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: LMA placement time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean changes in visual acuity letter score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TMJ pain during function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct number of RBC units ordered
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Crossmatch-to-transfusion ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Costs associated with blood ordering
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in domain-specific functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cure rates for STHs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Egg reduction rates for STHs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean STH egg count difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Energy percent (E%) fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of coronary heart disease (CHD)
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of cardiovascular disease (CVD)
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in under-treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in over-treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdominal discomfort score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toilet use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Aberrant Behavior Checklist‐‐Community Scale (ABC‐C) Irritability subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of nasal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modest health benefit
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: modified Rankin Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean fistula maturation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Six-month reintervention rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement in modified Rodnan skin score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in subjective self-assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean time intervals in response time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: correct patient identification time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: floor nurse satisfaction ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing